J. Russell Hoverman, MD, PhD

home / authors / j-russell-hoverman-md-phd

Articles

March 31st 2015

Cost Differential by Site of Service for Cancer Patients Receiving Chemotherapy

Jad Hayes, MS, ASA, MAAA J. Russell Hoverman, MD, PhD Matthew E. Brow, BA Dana C. Dilbeck, BA Diana K. Verrilli, MS Jody Garey, PharmD Janet L. Espirito, PharmD Jorge Cardona, BS Roy Beveridge, MD

The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.

May 24th 2012

Value-Based Reimbursement in Oncology

J. Russell Hoverman, MD, PhD

Getting On Pathway?

May 9th 2012

Impact of Payment Reform on Chemotherapy at the End of Life

Carrie H. Colla, PhD Nancy E. Morden, MD, MPH Jonathan S. Skinner, PhD J. Russell Hoverman, MD, PhD Ellen Meara, PhD

Payment reform may be used to better align appropriate financial incentives with better quality of care.

May 19th 2011

Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in 2 Distinct Databases

J. Russell Hoverman, MD, PhD Thomas H. Cartwright, MD Debra A. Patt, MD, MPH Janet L. Espirito, PharmD Matthew P. Clayton Jody S. Garey, PharmD Terrance J. Kopp Marcus A.

Retrospective evaluations of electronic health records and claims databases to assess clinical outcomes and costs associated with evidence-based pathways in colon cancer.